Idotrim

Trimethoprim, the active ingredient in Idotrim, is an antibiotic presented as an oral tablet for oral use. It treats urinary tract infections by targeting susceptible bacteria in patients requiring prescription therapy.

GNH USA supplies Idotrim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Idotrim is an antibacterial agent used to manage infections of the urinary tract and related conditions.

- Uncomplicated urinary tract infection: eradicates common uropathogens causing the infection. - Acute cystitis: relieves infection symptoms and promotes bacterial clearance. - Prophylaxis of recurrent urinary tract infections: reduces the frequency of future episodes.

Adverse reactions may occur with trimethoprim therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes. - Loss of appetite: reduced desire to eat. - Rash: mild skin irritation. - Headache: transient mild headache. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Stevens‑Johnson syndrome: rare severe skin disorder. - Blood dyscrasias: agranulocytosis, aplastic anemia, or severe leukopenia. - Kidney toxicity: impaired renal function. - Liver enzyme elevation: signs of hepatic stress.

Use trimethoprim with caution in specific clinical situations.

- Renal impairment: monitor kidney function and adjust therapy as needed. - Hepatic disease: use carefully; monitor liver enzymes. - Pregnancy: safety not established; avoid unless clearly indicated. - Concurrent folate antagonists: increased risk of bone‑marrow suppression. - Known hypersensitivity: discontinue immediately if allergic reaction occurs. - Store at ambient temperature: keep in original packaging, protect from moisture.

Trimethoprim may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Methotrexate: increased toxicity and risk of bone‑marrow suppression. - Phenytoin: reduced efficacy of trimethoprim, possible therapeutic failure. - Sulfonamides: additive folate antagonism leading to heightened toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, increasing bleeding risk. - ACE inhibitors: potential for hyperkalemia, especially in renal impairment. - Diuretics: may increase risk of renal dysfunction when combined.